TRAT1 (T cell receptor associated transmembrane adaptor 1) functions as a critical regulator of T cell receptor signaling and immune responses. The protein stabilizes the TCR/CD3 complex at the T cell surface and modulates intracellular signaling pathways 1. TRAT1 acts as a dual regulator of CD4+ T cell function by limiting effector activation through modulation of PI3K/AKT signaling pathways while supporting regulatory T cell-mediated suppression 1. The protein shows differential expression patterns, with reduced levels in regulatory T cells compared to effector T cells, and pronounced upregulation following T cell activation 1. TRAT1 deletion enhances T cell proliferation and activation marker expression but reduces IL-17 production through elevated STAT6 activity 1. In cancer contexts, TRAT1 promotes cytotoxicity in IL-17-producing CD8+ T cells through IL-4/AKT signaling-dependent TCR stabilization 2. Clinical relevance includes its association with various immune-related conditions: decreased expression correlates with poor prognosis in non-small cell lung cancer 3, while elevated expression is observed in celiac disease intestinal tissue as a potential biomarker 4. TRAT1 variants are also associated with clozapine-induced leukopenia and neutropenia risk 5, highlighting its broader immunological significance in drug-induced hematological adverse effects.